Why brain tumours are different
There is no stage I–IV for primary brain tumours. Staging elsewhere measures how far a cancer has travelled; brain tumours almost never leave the nervous system. What matters instead is WHO grade 1–4 (how aggressive the cells are), molecular markers, and where in the brain it sits — because location determines both what it does to you and whether it can be safely removed.
You may see SEER survival figures broken into "localized, regional, distant." For brain tumours those categories are close to meaningless — SEER itself classifies 77% as localized, and reports better survival for "distant" than "regional" disease, which tells you the framework does not fit. We are not reproducing that table for exactly that reason.
"Benign" needs care too. A grade 1 meningioma is not cancer and will not spread — but inside a rigid skull, a slowly growing mass can still press on structures that control speech, vision or movement. Benign brain tumours are often treated, and being told yours is benign is genuinely good news without meaning nothing needs doing.
Most brain tumours are secondary. Cancer that spreads to the brain from the lung, breast, melanoma or elsewhere is far more common than a cancer starting in the brain, and it is a different situation with different treatment. Ask which you have.
Who is at risk
- For most people, no cause is ever found. This is worth saying plainly, because the search for a reason can become its own burden.
- Prior radiation to the head, particularly in childhood — the one firmly established environmental risk factor.
- Inherited syndromes — neurofibromatosis 1 and 2, Li-Fraumeni, Turcot, von Hippel-Lindau, tuberous sclerosis. These account for a small minority.
- Age — most malignant brain tumours occur after 55, though brain tumours are also among the most common solid cancers of childhood.
- Sex and ethnicity — slightly more common in men, and notably more common in non-Hispanic White populations.
- A suppressed immune system raises the risk of CNS lymphoma specifically.
- Mobile phones have not been shown to cause brain tumours in large studies, despite persistent belief. Nor have head injuries, stress or diet.
Finding it early
There is no screening test for brain tumours, and scanning healthy people is not recommended — incidental findings are common and usually harmless, and chasing them causes real harm.
Symptoms depend entirely on location, which is why they are so varied:
- Headaches that are new and different — classically worse in the morning, worse on lying down, coughing or straining, and progressively more frequent. Most headaches are not tumours; a change in pattern is the signal.
- A first seizure in an adult — this always warrants brain imaging.
- New weakness or numbness on one side, difficulty finding words, personality or memory change, unsteadiness, or visual changes.
- Persistent nausea and vomiting, particularly with headache.
Go to an emergency department for a first seizure, sudden severe headache unlike any before, new weakness or confusion, or a rapidly worsening headache with vomiting.
How it’s diagnosed
MRI with contrast is the key imaging test — far more informative than CT for brain tumours, though CT is often done first in an emergency.
Tissue is what names it. A biopsy or surgical removal provides the diagnosis. Molecular testing is now part of the diagnosis itself, not an optional extra — the WHO classification integrates markers such as IDH mutation, 1p/19q co-deletion, MGMT methylation and others. Two tumours that look identical under the microscope can be entirely different diseases with different treatments and very different outlooks.
Ask for your integrated diagnosis — the full name including molecular findings, not just "brain tumour" or even "glioma." It is the single most useful thing to have written down.
Grade instead of stage
WHO grade 1 — slow-growing, often curable with surgery alone. Pilocytic astrocytoma and most meningiomas sit here.
WHO grade 2 — slow-growing but infiltrative, so complete removal is difficult. Often treated and monitored over years.
WHO grade 3 — anaplastic; more aggressive, usually needs surgery plus radiation and chemotherapy.
WHO grade 4 — includes glioblastoma, the most common malignant primary brain tumour in adults and the most difficult.
Molecular findings can move a tumour between categories entirely. An IDH-mutant tumour behaves very differently from an IDH-wildtype one that looks the same down a microscope, and the classification now reflects that.
Grading and biology
The markers worth knowing about, because they change treatment and outlook:
- IDH mutation — generally a better-behaving tumour with longer survival than an IDH-wildtype tumour of the same appearance.
- 1p/19q co-deletion — defines oligodendroglioma, which responds particularly well to chemotherapy and radiation.
- MGMT promoter methylation — predicts better response to temozolomide chemotherapy in glioblastoma.
- H3 K27M — defines diffuse midline glioma, an aggressive tumour occurring mainly in children and young adults.
Newer targeted drugs now exist for IDH-mutant low-grade glioma, which is a genuine change from a decade ago.
How it’s treated
Surgery comes first where it is safe. The goal is maximal safe removal — how much can be taken without causing lasting neurological damage. Awake craniotomy, intraoperative MRI and fluorescence guidance all exist to extend that boundary. Extent of removal measurably affects outcome for many tumours.
Radiation is central to brain tumour treatment, and this is squarely our field. Options include fractionated external radiation after surgery for higher-grade tumours; stereotactic radiosurgery, which delivers a precise high dose in one to five sessions and is standard for many brain metastases and selected benign tumours; and proton therapy, particularly valuable in children and in tumours near critical structures because it reduces dose to surrounding brain.
Chemotherapy — temozolomide for glioblastoma, PCV for oligodendroglioma. Tumour treating fields add benefit in glioblastoma. Targeted therapy exists for IDH-mutant gliomas and some other subtypes.
Steroids (dexamethasone) reduce swelling and can improve symptoms dramatically within days — but carry real side effects with prolonged use, so the aim is the lowest effective dose.
Where CureRays fits: radiation for brain tumours — including stereotactic radiosurgery for metastases — is core radiation oncology, and Dr. Hess trained as an NIH neuro-oncology research fellow at Dana-Farber studying brain tumours. If you want a radiation opinion here, this is a reasonable place to ask.
What the guidelines say
In broad strokes: obtain an MRI and then tissue for an integrated molecular diagnosis; achieve maximal safe surgical removal; follow with radiation and chemotherapy chosen by grade and molecular subtype; use stereotactic radiosurgery for limited brain metastases; and involve rehabilitation, seizure management and palliative care early rather than late.
Your team will follow national guidelines such as those from the National Comprehensive Cancer Network (NCCN). The above is a plain-language overview of the general approach, not the guideline itself. NCCN publishes free NCCN Guidelines for Patients®.
Outcomes and odds of cure
Overall 5-year relative survival for malignant brain and other nervous system cancer is 33.0% (NCI SEER, SEER 21 excluding IL, 2015–2021). In 2025 an estimated 24,820 people will be diagnosed and about 18,330 will die of it. Source: SEER Cancer Stat Facts: Brain and Other Nervous System Cancer.
That single number hides almost everything that matters. It averages a curable grade 1 tumour in a young person with glioblastoma in a 70-year-old. Outcomes range from cure to measured in months depending on grade, molecular subtype, age, how much was removed, and how well you are functioning at diagnosis.
On glioblastoma specifically, we are not going to soften it: it remains the hardest common brain tumour, typically measured in months to a few years rather than decades, though a meaningful minority live considerably longer — particularly younger patients with MGMT-methylated tumours and complete removal. People deserve to be told this straight, and also told that clinical trials are genuinely worth asking about here, because standard treatment has moved slowly.
Ask your neuro-oncologist for figures matched to your integrated diagnosis, age and extent of resection. Those numbers mean something; the population average does not.
These are population statistics from the National Cancer Institute's SEER program. They describe large groups of people, not any one person, and lag current treatment by several years. They cannot predict what will happen to you.
Side effects and how we watch for them
During radiation: fatigue that builds and can last months, hair loss in the treated area (sometimes permanent), scalp irritation, and temporary worsening of existing symptoms from swelling — managed with steroids.
Longer term: the honest concern is cognitive change — memory, attention and processing speed. Modern technique reduces this: hippocampal-sparing whole-brain radiation, stereotactic radiosurgery instead of whole-brain treatment where appropriate, and proton therapy in selected cases all exist specifically to protect thinking. Ask what your plan does to protect cognition. Also possible: hormone changes if the pituitary is in the field, hearing changes, and rarely radiation necrosis.
Steroids cause sleeplessness, mood change, raised blood sugar, weight gain and muscle weakness — often the most disruptive part of treatment day to day.
Seizures may need long-term anti-seizure medication, which affects driving eligibility — a practical consequence that hits hard and is often not discussed early enough.
How it is assessed: graded at each visit on a standard scale, with neurological examination and periodic MRI. Report new weakness, worsening headache, confusion or seizures promptly.
Follow-up, remission and survivorship
Follow-up is MRI-based, at intervals set by grade — every 2–3 months initially for high-grade tumours, stretching out over years for low-grade ones.
"Pseudoprogression" is worth knowing about: after chemoradiation, a scan can look worse because of treatment-related inflammation rather than tumour growth. It is common in the first months, and it is why your team may repeat a scan rather than change treatment immediately. That waiting period is agonising and it is not indecision.
Survivorship after a brain tumour is different from other cancers, because the organ affected is the one you think and feel with. Fatigue, cognitive change, mood and personality effects, epilepsy management, driving restrictions, return to work, and the impact on family all need active support. Neuropsychology, rehabilitation, occupational therapy and psychological support are not luxuries here.
Palliative care alongside active treatment improves quality of life and is not the same as giving up. For high-grade tumours it is worth involving early.
Questions people actually ask
What stage is my brain tumour?
Brain tumours are not staged like other cancers, because they almost never spread outside the nervous system. Ask for the grade (WHO 1–4) and the molecular findings instead — that is what determines treatment and outlook.
They said it's benign. Do I still need treatment?
Possibly. Benign means it will not spread — but inside a closed skull, even a slow-growing mass can press on structures that matter. Many benign tumours are watched; some are treated with surgery or radiosurgery. It is genuinely better news, not a guarantee of no treatment.
Did my mobile phone cause this?
Large studies have not shown that mobile phones cause brain tumours. Neither have head injuries, stress or diet. For most people no cause is ever identified, and the search for one can become its own burden.
My scan looks worse after radiation. Is it growing?
Not necessarily. Pseudoprogression — inflammation from treatment that mimics growth — is common in the first months after chemoradiation. Your team may repeat the scan rather than switch treatment. The wait is hard and it is the right call.
Will radiation affect my memory?
It can, and it is right to ask. Modern techniques exist specifically to reduce it — hippocampal sparing, stereotactic radiosurgery rather than whole-brain treatment where appropriate, and proton therapy in selected cases. Ask what your plan does to protect cognition.
Is it worth asking about a clinical trial?
Yes — particularly for glioblastoma and high-grade glioma, where standard treatment has improved slowly and trials are a genuine route to newer approaches. It is a reasonable question to raise at the first appointment, not the last.
Informational only, not medical advice — confirm with your care team.
Short-term side effects of radiotherapy to the brain and spine
Long-term side effects of radiotherapy to the brain and spine
Go deeper on brain tumours
Read the full plain-language guide, or ask our radiation team about radiosurgery and cognitive sparing.
Watch: Optune for glioblastoma
A plain-language explanation of Optune — tumor-treating fields — and where it fits alongside surgery, radiation and chemotherapy for glioblastoma.